A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an .alpha.-melanocyte stimulating hormone (.alpha.-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.